

A generic equivalent to PrTecfidera*

- > Appearance of the capsules similar to the reference product
- > Available in blisters indicating to patients when to take their medication (4 blisters of 14 capsules per box)

Appearance (actual size)	Strength	DIN	Format	UPC
PrSandoz® Dimethyl Fumarate Delayed-Release Capsules ———————————————————————————————————	120 mg Delayed-Release Capsules	02513781	Blisters of 56 (4 x 14 capsules)	0 57513 22197 2
PrSandoz® Dimethyl Fumarate Delayed-Release Capsules PrTecfidera*	240 mg Delayed-Release Capsules	02513803	Blisters of 56 (4 x 14 capsules)	0 57513 22198 9

^{™/®} Trademark and registered trademark owned or used under license by Sandoz Canada Inc.

Please consult Product Monograph available at sandoz.ca/en/Generics or obtain a copy by calling Sandoz Medical Information at 1-800-343-8839 ext. 4636.



 $^{^{\}ast}$ Registered trademark owned by its respective registrant.

PrSandoz®
Dimethyl Fumarate
Delayed-Release
Capsules



Support you can trust

Why choose Sandoz Continüm™?



SPEED

24-hour turnaround for enrolment



SIMPLICITY

Easy-to-complete enrollment form that requires only one signature, the patient's consent



EFFICIENCY

Electronic coverage speeds up payment process

What services are offered for PrSandoz® Dimethyl Fumarate Delayed-Release Capsules?†

Our experienced team of patient access specialists provide:



REIMBURSEMENT NAVIGATION

Regional expertise to help complete coverage requests



FINANCIAL ASSISTANCE

Financial support available, tailored to each patient's situation



EDUCATIONAL MATERIAL

Training for healthcare professionals about dosage adjustment and side effect management













For any questions or to obtain the enrollment form, please contact Sandoz Continüm™ at 1-888-6-SANDOZ (726369) or visit sandoz.ca/en/psp.

Please consult Product Monograph available at sandoz.ca/en/Generics or obtain a copy by calling Sandoz Medical Information at 1-800-343-8839 ext. 4636.



^{™/®} Trademark and registered trademark owned or used under license by Sandoz Canada Inc.

[†] Provincial exclusions may apply due to regulatory or other considerations

^{Pr}Sandoz[®] Dimethyl Fumarate Delayed-Release capsules (dimethyl fumarate delayed-release capsules) is indicated as monotherapy for the treatment of relapsing remitting multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of disability.